Dicerna Pharmaceuticals, Inc., A Novo Nordisk Company

This study tested a new drug called belcesiran in people with a genetic condition called Alpha-1 Antitrypsin Deficiency that causes liver damage. The goal was to see if the drug is safe and can lower harmful protein levels in the liver. The trial was stopped early, so results are…